ArticleJournal of thoracic disease2026
Safety analysis of long-acting dual bronchodilator after market approval: a real-world study from FDA Adverse Event Reporting System (FAERS) database.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Long-acting muscarinic antagonist (LAMA) and long-acting β2-agonist (LABA) combinations are widely prescribed for chronic obstructive pulmonary disease (COPD). This study evaluated post-marketing safety signals for four dual bronchodilators (formoterol/glycopyrronium, indacaterol/glycopyrronium, vilanterol/umeclidinium, and olodaterol/tiotropium). Methods: A retrospective pharmacovigilance study of four bronchodilators was conducted using the data from Food and Drug Administration Adverse Event Reporting System (FAERS) database between January 1, 2014 and March 31, 2025. The association between drugs and adverse events (AEs) was evaluated using reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPN), and multi-item gamma Poisson shrinker (MGPS). Venn analysis was performed to identify drug-specific disproportionality signals for the four bronchodilators. Results: A total of 18,677 cases were included. Venn analysis identified 13 common safety signals and various drug-specific disproportionality safety signals, including 56 important medical events (IMEs) that met signaling thresholds for only one drug. Urinary retention emerged as a common IME among four bronchodilators. Indacaterol/glycopyrronium was associated with distinct cardiovascular risks, including arrhythmia, cardiac arrest, myocardial infarction, angina pectoris, and coronary artery disease. Olodaterol/tiotropium showed signals for ileus, retinal vein occlusion, cataract, and hip fracture, and exhibited the longest latency period among the other three bronchodilators. Conclusions: This pharmacovigilance study identified significant safety signals associated with four bronchodilators, highlighting both common and drug-specific disproportionality signals and thereby providing essential evidence to support drug monitoring in clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.